A detailed history of Massachusetts Financial Services CO transactions in Novavax Inc stock. As of the latest transaction made, Massachusetts Financial Services CO holds 93,457 shares of NVAX stock, worth $791,580. This represents 0.0% of its overall portfolio holdings.

Number of Shares
93,457
Previous 75,228 24.23%
Holding current value
$791,580
Previous $952,000 23.95%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$10.71 - $17.11 $195,232 - $311,898
18,229 Added 24.23%
93,457 $1.18 Million
Q2 2024

Aug 09, 2024

BUY
$3.89 - $20.97 $292,636 - $1.58 Million
75,228 New
75,228 $952,000
Q1 2023

May 10, 2023

SELL
$5.76 - $12.48 $2,966 - $6,427
-515 Reduced 2.76%
18,120 $125,000
Q4 2022

Feb 13, 2023

BUY
$8.86 - $25.04 $3,499 - $9,890
395 Added 2.17%
18,635 $191,000
Q3 2022

Nov 09, 2022

SELL
$18.2 - $76.12 $3,021 - $12,635
-166 Reduced 0.9%
18,240 $332,000
Q2 2022

Aug 09, 2022

BUY
$36.28 - $75.29 $348,505 - $723,235
9,606 Added 109.16%
18,406 $947,000
Q1 2022

May 11, 2022

BUY
$69.73 - $142.9 $613,624 - $1.26 Million
8,800 New
8,800 $648,000
Q4 2021

Feb 10, 2022

SELL
$134.56 - $217.97 $637,007 - $1.03 Million
-4,734 Closed
0 $0
Q3 2021

Nov 10, 2021

SELL
$177.8 - $270.58 $819,124 - $1.25 Million
-4,607 Reduced 49.32%
4,734 $981,000
Q2 2021

Aug 13, 2021

SELL
$121.0 - $257.67 $978,527 - $2.08 Million
-8,087 Reduced 46.4%
9,341 $1.98 Million
Q1 2021

May 13, 2021

SELL
$112.98 - $319.93 $237,935 - $673,772
-2,106 Reduced 10.78%
17,428 $3.16 Million
Q4 2020

Feb 12, 2021

SELL
$78.74 - $139.5 $15,590 - $27,621
-198 Reduced 1.0%
19,534 $2.18 Million
Q3 2020

Nov 12, 2020

BUY
$79.44 - $178.51 $1.57 Million - $3.52 Million
19,732 New
19,732 $2.14 Million

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $662M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Massachusetts Financial Services CO Portfolio

Follow Massachusetts Financial Services CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Massachusetts Financial Services CO , based on Form 13F filings with the SEC.

News

Stay updated on Massachusetts Financial Services CO with notifications on news.